SEC Form 4 · accession 0001209191-18-021896
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fletcher Payne
Officer — Chief Financial Officer
Period of report
Mar 26, 2018
Accepted (ET)
Mar 28, 2018 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 26, 2018 | M | 59 | $4.63 | A | 59 | D | |
| Common StockF1 | holding | — | — | — | 1,668 | I | By Charles and Nancy Payne 2000 Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.63 | Mar 26, 2018 | M | 59 | D | — | Jul 11, 2027 | Common Stock | 59 | 74,941 | D |
Explanation of responses
- F1Reflects a 1:15 reverse stock split effected on February 10, 2017.
- F2The Option vests monthly over a period of four years commencing June 15, 2017.